Dataset Information

Predicting Venous Thromboembolic Events in Patients with Coronavirus Disease 2019 Requiring Hospitalization: an Observational Retrospective Study by the COVIDIC Initiative in a Swiss University Hospital.

ABSTRACT: Background: Coronavirus disease 2019 (COVID-19) can result in profound changes in blood coagulation. The aim of the study was to determine the incidence and predictors of venous thromboembolic events (VTE) among patients with COVID-19 requiring hospital admission. Subjects and Methods. We performed a retrospective study at the Lausanne University Hospital with patients admitted because of COVID-19 from February 28 to April 30, 2020.

Results: Among 443 patients with COVID-19, VTE was diagnosed in 41 patients (9.3%; 27 pulmonary embolisms, 12 deep vein thrombosis, one pulmonary embolism and deep vein thrombosis, one portal vein thrombosis). VTE was diagnosed already upon admission in 14 (34.1%) patients and 27 (65.9%) during hospital stay (18 in ICU and nine in wards outside the ICU). Multivariate analysis revealed D-dimer value > 3,120?ng/ml (P < 0.001; OR 15.8, 95% CI 4.7-52.9) and duration of 8 days or more from COVID-19 symptoms onset to presentation (P 0.020; OR 4.8, 95% CI 1.3-18.3) to be independently associated with VTE upon admission. D-dimer value ? 3,000?ng/l combined with a Wells score for PE ? 2 was highly specific (sensitivity 57.1%, specificity 91.6%) in detecting VTE upon admission. Development of VTE during hospitalization was independently associated with D-dimer value > 5,611?ng/ml (P < 0.001; OR 6.3, 95% CI 2.4-16.2) and mechanical ventilation (P < 0.001; OR 5.9, 95% CI 2.3-15.1).

Conclusions: VTE seems to be a common COVID-19 complication upon admission and during hospitalization, especially in ICU. The combination of Wells ? 2 score and D - dimer ? 3,000?ng/l is a good predictor of VTE at admission.

SUBMITTER: Kampouri E

PROVIDER: S-EPMC7656238 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Predicting Venous Thromboembolic Events in Patients with Coronavirus Disease 2019 Requiring Hospitalization: an Observational Retrospective Study by the COVIDIC Initiative in a Swiss University Hospital.

Kampouri Eleftheria E Filippidis Paraskevas P Viala Benjamin B Méan Marie M Pantet Olivier O Desgranges Florian F Tschopp Jonathan J Regina Jean J Karachalias Eleftherios E Bianchi Christophe C Zermatten Maxime G MG Jaton Katia K Qanadli Salah Dine SD Bart Pierre-Alexandre PA Pagani Jean-Luc JL Guery Benoit B Alberio Lorenzo L Papadimitriou-Olivgeris Matthaios M RegCOVID Research Group

BioMed research international 20201106

<h4>Background</h4>Coronavirus disease 2019 (COVID-19) can result in profound changes in blood coagulation. The aim of the study was to determine the incidence and predictors of venous thromboembolic events (VTE) among patients with COVID-19 requiring hospital admission. <i>Subjects and Methods</i>. We performed a retrospective study at the Lausanne University Hospital with patients admitted because of COVID-19 from February 28 to April 30, 2020.<h4>Results</h4>Among 443 patients with COVID-19, ...[more]

PMID: 33204727

Similar Datasets

Project description:BACKGROUND:Men die earlier than women in Germany. Men also have impaired access to cancer screening compared to women. OBJECTIVES:Our Movember campaign 2019 at University Hospital Frankfurt (UKF) aimed at improving health care awareness in the context of prostate cancer checkup. MATERIALS AND METHODS:In November 2019, every male employee of the UKF with a minimum age of 45 yrs (or 40 yrs with a first degree relative with prostate cancer) was offered a free prostate cancer checkup. This checkup contained digital rectal examination (DRE), transrectal ultrasound and PSA (prostata-specific antigen) testing. RESULTS:Overall, 121/840 employees (14.4%) participated in the Movember campaign. A first degree relative with prostate cancer was reported in overall by 14% of the participants (n?=?17). At least one prior prostate cancer check up had 33%. A total of 2.5% (n?=?3) had one prior negative prostate biopsy. Median age was 54 yrs (interquartile range 50-58). Median PSA level was 0.9?ng/ml and median free-PSA 0.3?ng/ml. A suspicious DRE was found in 5% (n?=?6). After stratification according to age (??50 yrs vs. >?50 yrs), participants over 50 yrs had a significantly higher PSA level (1.0?ng/ml vs. 0.7?ng/ml, p?<?0.01) and had more frequently at least one prior prostate cancer checkup in the past (42.0 vs. 12.1%, p?<?0.01). All suspicious DREs were in the cohort >?50 yrs. Overall, 32.2% (n?=?39) had at least a suspicious checkup. A total of 3.3% (n?=?4) had suspicious PSA levels. 17.4% (n?=?21) of the participants had a suspicious PSA ratio (<?20%) only. During follow-up, 6 prostate biopsies were performed, with the detection of one case of intermediate-risk prostate cancer (Gleason 3?+?4, pT3a, pPn1, pNx, R0). CONCLUSION:Overall, 121 employees participated in our Movember Prostate cancer checkup campaign with measurement of the PSA level. Suspicious results were recorded in 32.2%. One employee was diagnosed and successfully treated with an intermediate-risk prostate cancer.

Dataset Information

Predicting Venous Thromboembolic Events in Patients with Coronavirus Disease 2019 Requiring Hospitalization: an Observational Retrospective Study by the COVIDIC Initiative in a Swiss University Hospital.

Publications

Predicting Venous Thromboembolic Events in Patients with Coronavirus Disease 2019 Requiring Hospitalization: an Observational Retrospective Study by the COVIDIC Initiative in a Swiss University Hospital.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure